Blog

Combining PIPAC with systemic chemotherapy in colorectal and appendiceal cancer – City of Hope

Pashtoon Kasi/LinkedIn

Mar 18, 2025, 07:13

Combining PIPAC with systemic chemotherapy in colorectal and appendiceal cancer – City of Hope

City of Hope posted on LinkedIn:

“A phase 1 clinical trial led by researchers at City of Hope has demonstrated the safety and early efficacy of combining pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy for patients with colorectal and appendiceal cancer that has spread to the peritoneum of the abdominal cavity.

This promising research will be featured at a March 18 press briefing highlighting some of the most consequential advancements to be presented at this year’s Society of Surgical Oncology Annual Meeting (SSO2025).

Of all possible sites where cancer can spread, peritoneal metastases are among the most challenging to treat. Systemic chemotherapy struggles to reach this region due to its low vascularity, leading to poor survival rates. Without intervention, patients with peritoneal metastases often survive only a few months, with few surpassing one year on standard treatment.

City of Hope’s researchers are working to change that.

‘Up until recently, delivering a uniform dose of chemotherapy in the abdomen has not been possible. At City of Hope, we have been evaluating the use of PIPAC, which is the most optimized way to deliver chemotherapy in the abdominal cavity. It increases targeted medicinal exposure while limiting toxicity,’ said Mustafa Raoof, M.D., M.S., assistant professor in City of Hope’s Division of Surgical Oncology.

Learn more.”

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared this post on LinkedIn, adding:

“One more option/tool for our patients at City of Hope. PIPAC – Pressurized IntraPeritoneal Aerosol Chemotherapy.”